EPIC SCIENCES AND FULGENT GENETICS COLLABORATE TO DELIVER DefineMBC™ RESULTS FOR METASTATIC BREAST CANCER PATIENTS

Epic Sciences scales its workflow for ctDNA testing with Next Generation Sequencing Leader Fulgent

Fulgent Genetics’ expertise in high-volume testing powers Epic’s Comprehensive Cancer Profiling

Excerpt from the Press Release:

SAN DIEGO, Feb. 24, 2022 /PRNewswire/ –Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients. The partnership links Fulgent’s leading CAP/CLIA certified Next Generation Sequencing services with Epic’s best-in-class cell analysis platform as part of Epic’s novel DefineMBC liquid biopsy test.

DefineMBC includes both cell-based and cell-free analysis from a single blood draw to provide comprehensive MBC profiling when a tissue biopsy result is not available. The test’s multi-analyte methods have demonstrated impressive sensitivity, specificity, accuracy, and precision in the:

• detection of circulating tumor cells (CTCs)
• assessment of protein expression (HER2, ER)
• determination of intra-cell copy number variation (CNV) of CTCs
• plasma-based cell-free DNA analysis for identification of single nucleotide variants (SNVs), indels, fusions, CNVs, as well as
• the calculation of microsatellite instability (MSI) and tumor mutational burden (TMB)

Fulgent Genetics offers over 19,000 unique genomic testing solutions and was one of the first clinical laboratories to offer CNV detection using NGS technology in the United States. Its clinical lab is CLIA-certified/CAP accredited, and all specimens are sequenced in its US-based laboratories in California and Texas.

Click the button below to read the entire Press Release:

Continue Reading The Press Release